Ipamorelin — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Selective growth-hormone secretagogue (ghrelin mimetic)
Reported half-life: Approximately 2 hours
Routes used in the literature: Subcutaneous and intravenous in published work
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Human phase 2 post-operative ileus trials

Reported quantity: 0.03 mg/kg per administration (roughly 2 mg for an 70 kg participant)
Frequency: Twice daily by intravenous infusion
Study duration: Up to 7 days post-operatively

This is the best-documented human figure for the compound.

Growth-hormone release pharmacology studies

Reported quantity: 0.1–1.0 µg/kg producing measurable GH pulses
Frequency: Single administration for pulse measurement
Study duration: Single timepoint series over 2–4 hours

Selectivity — minimal cortisol and prolactin movement — is the compound's defining published feature.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

Ipamorelin · 10 mg Vial

Ipamorelin is dosed at 100 mcg–250 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range: 100–300 mcg once daily (gradual titration recommended).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33 mcg on a U-100 insulin syringe.
Storage: Lyophilized: 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~4 weeks.

Standard / Gradual Approach (3.0 mL = ~3.33 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	100 mcg	3 units (0.03 mL)
Weeks 3–4	150 mcg	5 units (0.05 mL)
Weeks 5–8	200 mcg	6 units (0.06 mL)
Weeks 9–12	250 mcg	8 units (0.08 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size Ipamorelin is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

Ipamorelin · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	100 mcg =	300 mcg =
2 mg	0.67 mg/ml	7 mcg	15 units	45 units
5 mg	1.67 mg/ml	17 mcg	6.0 units	18 units
10 mg	3.33 mg/ml	33 mcg	3.0 units	9.0 units

Unit columns use the range reported for this compound (100 mcg–300 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL, so 0.1 mL on an insulin syringe draws 250 µg.

Open the reconstitution calculator

How to read these figures

GH secretagogues act on the pituitary; published pulses depend heavily on timing relative to food and sleep.
Ipamorelin's selling point in the literature is selectivity, not magnitude of GH release.
Long-term human exposure data does not exist for this compound.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998 · PMID 9849822
In vitro and in vivo (rat and pig) studies characterized ipamorelin dosing that selectively releases GH without affecting cortisol, ACTH, or prolactin.
View the record
[2]
Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers
Gobburu JV, Agerso H, Jusko WJ, Ynddal L. · Pharmaceutical Research · 1999 · PMID 10496658
Healthy human volunteers received intravenous ipamorelin doses to model pharmacokinetic-pharmacodynamic relationships for GH release.
View the record
[3]
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Johansen PB, Nowak J, Skjaerbaek C, et al. · Growth Hormone & IGF Research · 1999 · PMID 10373343
Rats received repeated subcutaneous ipamorelin injections to assess dose-dependent effects on GH secretion and longitudinal bone growth.
View the record

Search the databases yourself

Read the Ipamorelin research brief

Other growth hormone compounds

AOD-9604hGH fragment 176-191 CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogue CJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blend CJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.